Skip to content

Author

Robert D. Morgan

We have 2 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review.

Importance Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remains poor for the substantial subset of patients whose tumors respond insufficiently to platinum-based chemotherapy and who, therefore, frequen...

Benoît You, A. Clamp, K. Moore et al. · 0 citations
Aug 2026

Risk of breast cancer after ovarian cancer in germline BRCA1/2 heterozygotes.

Breast cancer risk after ovarian cancer in germline BRCA1/2 heterozygotes remains uncertain, with a recent large multicentre international study reporting lower-than-expected incidence in the first decade after ovarian cancer diagnosis (Apostol et al. 2026). We re‑evaluated our previously published regional cohort of 7...

Robert D. Morgan, E. Woodward, D. G. Evans · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.